Antisperm antibodies in women undergoing intrauterine insemination
article
OA: closed
CC0
⤵ 1 in-corpus citation
Abstract
Intrauterine insemination is widely used for the treatment of infertility as a result of cervical or male factors or empirically before in vitro fertilization or gamete intrafallopian transfer. This study was designed to confirm or refute the theoretical concern that intrauterine insemination may induce antisperm antibodies in such women. Serum and cervical mucus were obtained at the first, fourth, and sixth intrauterine inseminations. The serum was screened by the Immunobead test for IgG and IgA. If screening results were positive (greater than 10% binding), antisperm antibodies were titered by the microimmobilization and microagglutination tests. The Immunobead test was performed on the cervical mucus after liquefication with bromelin. Ninety-three patients were followed up prospectively. Of these, 40 completed six intrauterine insemination cycles and the remaining 53 completed four cycles. Low transient antisperm antibody levels were detected in 10.8% of the patients and would not be expected to affect the prognosis for fertility. It is concluded that intrauterine insemination does not induce significant antisperm antibody production in women.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (1)
References (19)
- W21743954 via openalex
- W36756522 via openalex
- W72918047 via openalex
- W1548144407 via openalex
- W1560046309 via openalex
- W1588492717 via openalex
- W1966042645 via openalex
- W1991242621 via openalex
- W2007477163 via openalex
- W2072388395 via openalex
- W2110453076 via openalex
- W2129679270 via openalex
- W2396394444 via openalex
- W2396572107 via openalex
- W2406438279 via openalex
- W2411785081 via openalex
- W2412055784 via openalex
- W2412607508 via openalex
- W4313311495 via openalex
Cited by (1)
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK